Download PDF
Diabetologie und Stoffwechsel 2021; 16(01): 38-49
DOI: 10.1055/a-1156-9957
CME-Fortbildung

Therapie des Diabetes bei chronischer Niereninsuffizienz

Treatment of diabetes in patients with chronic kidney disease
Martina Guthoff
,
Ludwig Merker
› Further Information
Also available at
    Permissions and Reprints

In kaum einem anderen Bereich der Inneren Medizin hat sich in den letzten Jahren so viel getan wie in der Diabetologie. Unerwartet und überraschend haben neue Diabetesmedikamente gezeigt, dass sie nicht nur Blutglukose und Gewicht günstig beeinflussen, sondern auch einen signifikanten und über das Maß der Blutzuckerverbesserung hinausgehenden Einfluss auf das kardiovaskuläre Überleben haben. Viele dieser neu entwickelten Medikamente und Therapien sind nicht bei allen Stadien der chronischen Niereninsuffizienz einfach anwendbar und zugelassen. Es sind unter anderem Veränderungen des Metabolismus, die die chronische Niereninsuffizienz mit sich bringt, zu bedenken.

Abstract

Chronic kidney disease (CKD) is highly prevalent in patients with diabetes mellitus and has relevant impact on glucose metabolism, monitoring of such, and treatment options. In patients with higher grades of CKD and more prevalent cardiovascular disease, treatment-associated risk increases, necessitating adapted treatment goals. Novel treatment options for patients with type 2 diabetes with the potential for inhibition of both, cardiovascular and renal progression, have led to a rethinking of diabetes therapy. Currently, dialysis patients are mostly excluded from these medications; insulin treatment has to be adapted to the modality of the renal replacement therapy. In type 1 diabetes, modern diabetes technology has improved both quality of life as well as glucose control. These technologies are of special interest in patients with CKD. An interdisciplinary approach of primary care physicians, diabetologists and nephrologists is required for optimal treatment in patients with diabetes and CKD.

Schlüsselwörter

Diabetes mellitus - chronische Niereninsuffizienz - Glukosemetabolismus - Therapieziele - Monitoring

Key words

diabetes mellitus - chronic kidney disease - glucose metabolism - treatment goals - monitoring


Publication History

Article published online:
01 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kramer A, Boenink R, Noordzij M. et al The ERA-EDTA Registry Annual Report 2017: a summary. Clin Kidney J 2020; 13 (04) 693-709 . doi:sfaa048, doi:10.1093/ckj/sfaa048
    CrossrefPubMedGoogle Scholar
  • 2 Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3: 19-62 . doi:10.1038/kisup.2012.64
    CrossrefPubMedGoogle Scholar
  • 3 Merker L, Bautsch B-W, Ebert T. et al Nephropathie bei Diabetes. Diabetol Stoffwechs 2020; 15: S170-S174
    Article in Thieme ConnectGoogle Scholar
  • 4 Nationale Diabetes-Surveillance am Robert Koch-Institut (2019). Diabetes in Deutschland – Bericht der Nationalen Diabetes-Surveillance. Berlin: Robert Koch-Institut; 2019
    PubMedGoogle Scholar
  • 5 Guthoff M, Wagner R, Vosseler D. et al Impact of end-stage renal disease on glucose metabolism – a matched cohort analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 2017; 32: 670-676 . doi:10.1093/ndt/gfx018
    Google Scholar
  • 6 Hung AM, Ikizler TA. Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol 2011; 171: 127-134 . doi:10.1159/000327177
    CrossrefPubMedGoogle Scholar
  • 7 Duckworth WC, Kitabchi AE. Insulin metabolism and degradation. Endocr Rev 1981; 2: 210-233 . doi:10.1210/edrv-2-2-210
    CrossrefPubMedGoogle Scholar
  • 8 Hill CJ, Maxwell AP, Cardwell CR. et al Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis Off J Natl Kidney Found 2014; 63: 84-94 . doi:10.1053/j.ajkd.2013.06.020
    CrossrefPubMedGoogle Scholar
  • 9 Schwaiger E, Burghart L, Signorini L. et al Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2019; 19 (03) 907-919
    CrossrefPubMedGoogle Scholar
  • 10 Mahling M, Schork A, Nadalin S. et al Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019; 44 (05) 984-992
    CrossrefPubMedGoogle Scholar
  • 11 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98: S1-S115 . doi:10.1016/j.kint.2020.06.019
    CrossrefPubMedGoogle Scholar
  • 12 Landgraf R, Aberle J, Birkenfeld AL. et al Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 2019; 14: S167-S187 . doi:10.1055/a-0898-9617
    Article in Thieme ConnectGoogle Scholar
  • 13 Zelniker TA, Wiviott SD, Raz I. et al SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39 . doi:10.1016/S0140-6736(18)32590-X
    CrossrefPubMedGoogle Scholar
  • 14 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-1446 . doi:10.1056/NEJMoa2024816
    CrossrefPubMedGoogle Scholar
  • 15 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; DOI: 10.1056/NEJMoa2025845.
    CrossrefPubMedGoogle Scholar
  • 16 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 . doi:10.1093/eurheartj/ehz455
    CrossrefPubMedGoogle Scholar
  • 17 Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol 2015; 11: 302-313 . doi:10.1038/nrneph.2015.38
    CrossrefPubMedGoogle Scholar
  • 18 Idorn T, Knop FK, Jørgensen MB. et al Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care 2016; 39: 206-213 . doi:10.2337/dc15-1025
    CrossrefPubMedGoogle Scholar
  • 19 Yates CJ, Fourlanos S, Colman PG. et al Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation 2013; 96: 726-731 . doi:10.1097/TP.0b013e3182a012f3
    CrossrefPubMedGoogle Scholar
  • 20 Lindahl JP, Hartmann A, Horneland R. et al Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. Diabetologia 2013; 56: 1364-1371 . doi:10.1007/s00125-013-2888-y
    CrossrefPubMedGoogle Scholar
  • 21 Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol JASN 2010; 21: 383-385 . doi:10.1681/ASN.2010010031
    CrossrefPubMedGoogle Scholar
  • 22 Peacock TP, Shihabi ZK, Bleyer AJ. et al Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068 . doi:10.1038/ki.2008.25
    CrossrefPubMedGoogle Scholar
  • 23 Mian Z, Hermayer KL, Jenkins A. Continuous glucose monitoring: review of an innovation in diabetes management. Am J Med Sci 2019; 358: 332-339 . doi:10.1016/j.amjms.2019.07.003
    CrossrefPubMedGoogle Scholar